An update on sleep disorders and their treatment

Progress in Neurology and Psychiatry

Volumn 17, Issue 5, 2013, Pages 15-23

  Sie, Michele ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CLOMETHIAZOLE; CLONAZEPAM; CLONIDINE; DEXAMPHETAMINE; FLUOXETINE; HYPNOTIC AGENT; IMIPRAMINE; MELATONIN; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; NEUROTRANSMITTER; OXYBATE SODIUM; PAROXETINE; PRAZOSIN; PROMETHAZINE; REBOXETINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABDOMINAL PAIN; ABNORMAL THINKING; AGGRESSION; ALOPECIA; ANOREXIA; ANXIETY; ARTHRALGIA; ASTHENIA; ATAXIA; ATTENTION; BACKACHE; BEDTIME DOSAGE; BLOOD PRESSURE; BLURRED VISION; COGNITIVE THERAPY; CONFUSION; CONSTIPATION; COUGHING; DAYTIME SOMNOLENCE; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG SAFETY; DYSKINESIA; DYSPEPSIA; DYSPHORIA; EDEMA; EUPHORIA; FAINTNESS; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERSOMNIA; HYPERTENSION; HYPESTHESIA; INSOMNIA; IRRITABILITY; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; LOSS OF APPETITE; MENTAL OVERSTIMULATION; MOUTH ULCER; MUSCLE CRAMP; MYALGIA; NARCOLEPSY; NAUSEA; NAUSEA AND VOMITING; NERVOUSNESS; NIGHTMARE; NOCTURNAL ENURESIS; NONREM SLEEP; NOSE IRRITATION; NOSE OBSTRUCTION; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARESTHESIA; PERIPHERAL EDEMA; PHARYNGITIS; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PRURITUS; RASH; REM SLEEP; RESTLESS LEGS SYNDROME; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP STAGE; SLEEP WAKING CYCLE; SLEEP WALKING; SOMNOLENCE; SWEATING; TACHYCARDIA; TASTE DISORDER; THORAX PAIN; TIC; TREATMENT OUTCOME; TREMOR; UNSTEADINESS; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION; VASODILATATION; VERTIGO; VOMITING; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84885809762     PISSN: 13677543     EISSN: 1931227X     Source Type: Journal    
DOI: 10.1002/pnp.299     Document Type: Review

References (54)

1. Klerman E, Dijk D. Age-related reduction in the maximal capacity for sleep -Implications for insomnia. Current Biology 2008;18:1118-23.
2. Carskadon M, Dement, W. Normal human sleep: An overview. In: M Kryger, T Roth, W Dement (eds). Principles and Practice of Sleep Medicine, 3rd edn. Philadelphia: WB Saunders 2000;15-25.
3. Besset A. Guidelines for visual sleep analysis. In: M Billiard, ed. Sleep: Physiology, Investigations and Medicine. New York: Kluwer Academic/Plenum Publishers, 2003;151-8.
4. Boutrel B, Koob G. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 2004;27(6):1181-94.
5. Gottesmann, C. GABA mechanisms and sleep. Neuroscience 2002;111(2):231-9.
6. Zhdanova I, Wurtman R, Regan M, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001;86(10):4727-30.
7. Sakurai T, Mieda M, Tsujino N. The orexin system: roles in sleep/wake regulation. Ann N Y Acad Sci 2010;1200:149-61.
8. World Health Organization. International Classification of Disease Version 10 (ICD-10). WHO, 2010. http://apps.who.int/classifications/ icd10/browse/2010/en
9. Ohayon MM, Partinen M. Insomnia and global sleep dissatisfaction in Finland. J Sleep Res 2002;11: 339-46.
10. Ram S, Seirawan H, Kumar SK, et al. Prevalence and impact of sleep disorders and sleep habits in the United States. Sleep Breath 2010;14: 63-70.
11. Connor J, Whitlock G, Norton R, et al. The role of driver sleepiness in car crashes: a systematic review of epidemiological studies. Accid Anal Prev 2001;33(1):31-41.
12. Mountain SA, Quon BS, Dodek P, et al. The impact of housestaff fatigue on occupational and patient safety. Lung 2007;185(4):203-9.
13. Wells ME, Vaughn BV. Poor sleep challenging the health of a nation. Neurodiagnostic J 2012;52:233-49.
14. Spiegel K, Tasali E, Leproult R, et al. Effects of poor and short sleep on glucose metabolism and obesity risk. Nat Rev Endocrinol 2009;5:253-61.
15. Gangwisch J, Heymsfield S, Boden-Albala B, et al. Short sleep duration as a risk factor for hypertension. Hypertension 2006;47:833.
16. Roux F. Sleep-related breathing disorders and cardiovascular disease. Am J Med 2000;108(5):396-402.
17. Groegerf JA, Zijlstra FR, Dijk D. Sleep quantity, sleep difficulties and their perceived consequences in a representative sample of some 2000 British adults. J Sleep Res 2004;13:359-71.
18. Cowen P, Harrison P, Burns T. Shorter Oxford Textbook of Psychiatry, 6th Edn. Oxford University Press, 2012.
19. Bender B, Leung, D. Sleep disorders in patients with asthma, atopic dermatitis, and allergic rhinitis. J Allergy Clin Immunol 2005; 116(6):1200-1.
20. Moldofsky H. Sleep and pain. Sleep Medicine Reviews 2001;5(5): 385-96.
21. Roth T, Franklin M, Bramley T. The state of insomnia and emerging trends. Am J Manag Care 2007;13:S117-S120.
22. Daley M, Morin C, LeBlanc M, et al. The economic burden of insomnia: Direct direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep 2009;32(1):55-64.
23. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010;24(11):1577-1600.
24. National Institute for Health and Clinical Excellence Technology Appraisal (TA) 77. Insomnia -newer hypnotic drugs: guidance. NICE, 2004. http://guidance.nice.org.uk/TA77/Guidance/pdf/English
25. British National Formulary (BNF) 65. March-September 2013. London: BMJ Group and RPS Publishing, 2013.
26. Brunton L, Goodman L, Blumenthal D, et al. Goodman and Gilman's Manual of Pharmacology and Therapeutics. USA: Mcgraw HillCompanies, 2008:262-79.
27. Hartmann E, Cravens J. The effects of long-term administration of psychotropic drugs on human sleep: V. The effects of chloral hydrate. Psychopharmacologia 1973;33(3):219-32.
28. Nolen TM. Sedative effects of antihistamines: safety, performance, learning and quality of life. Clin Therapeutics 1997;19:39-55.
29. Sateia M, Nowell P. Insomnia. Lancet 2004;364:1959-73.
30. Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. Neuropsychiatr Dis Treat 2009:5;341-54.
31. Dorland's Medical Dictionary for Health Consumers. Saunders, an imprint of Elsevier, Inc, 2010. http://medical-dictionary. thefreedictionary.com
32. Lexicon of Alcohol and Drug Terms. World Health Organization, 2010. http://www.who.int/substance_abuse/terminology/who_lexicon/ en/print.html
33. Tyrer P, Silk KR, eds. Treatment of sedative-hypnotic dependence. Cambridge Textbook of Effective Treatments in Psychiatry, 1st edn. Cambridge University Press, 2008.
34. Waller D, Renwick A, Hillier K. Anxiolytics, Sedatives and Hypnotics in Medical Pharmacology and Therapeutics, 3rd edn. Edinburgh: Harcourt Publishers Ltd, 2009.
35. Hajak G, Müller W, Wittchen H, et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003:98;1371-8.
36. Bazire S. Psychotropic Drug Directory. Lloyd-Reinhold Communications LLP, 2012.
37. Pagel J. Excessive daytime sleepiness. Am Family Physician 2009;79(5):391-6.
38. Mieda MM, Sakurai, T. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. CNS Drugs 2013;27(2): 83-90.
39. Morgenthaler T, Kapur V, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin: An American Academy of Sleep Medicine report. Sleep 2007;30(12):1705-11.
40. Young J. Dopamine D1 and D2 receptor family contributions to modafinil-induced wakefulness. J Neurosci 2009;29(9):2663-5.
41. Black J, Houghton W. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006;29(7):939-46.
42. Minzenberg MS, Carter CS. Modafinil neurochemistry and cognition. Neuropsychopharmacology 2008;33:1477-1502.
43. Lurie A. Obstructive sleep apnea in adults: epidemiology, clinical presentation, and treatment options. Adv Cardiol 2011;46:1-42.
44. http://guidance.nice.org.uk/TA139/QuickRefGuide/pdf/English
45. Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults -an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses. Sleep 2012;35(8):1039-62.
46. Karatas M. Restless legs syndrome and periodic limb movements during sleep: diagnosis and treatment. The Neurologist 2007;13(5):294-301.
47. Comella C. Restless legs syndrome treatment with dopaminergic agents. Neurology 2002;58:87-92.
48. Cohrs S. Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs 2008;22(11):939-62.
49. Lancee J, Spoormaker V, Krakow B, et al. A systematic review of cognitive-behavioral treatment for nightmares: toward a well-established treatment. J Clin Sleep Med 2008;4(5):475-80.
50. Aurora RN, Zak RS, Auerbach SH, et al. Best practice guide for the treatment of nightmare disorder in adults. J Clin Sleep Med 2010; 6(4):389-401.
51. Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010;6(1):85-95.
52. Paparrigopoulos T. REM sleep behaviour disorder: Clinical profiles and pathophysiology. Int Review of Psychiatry 2005;17(4):293-300.
53. Thorpy M, Plazzi G. The parasomnias and other sleep-related movement disorders. Cambridge University Press, 2010.
54. US National Institutes of Health. http://clinicaltrials.gov/ct2/home